Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration

Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended in preterm infants born at 29 weeks gestationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Packnett, Elizabeth R., Winer, Isabelle H., Oladapo, Abiola, Wojdyla, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Passive Immunization
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578184/
https://www.ncbi.nlm.nih.gov/pubmed/37828711
http://dx.doi.org/10.1080/21645515.2023.2252289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578184/
https://www.ncbi.nlm.nih.gov/pubmed/37828711
http://dx.doi.org/10.1080/21645515.2023.2252289

Ejemplares similares